Here is a number worth sitting with: 43% of insured Americans were prescribed a medication they found too expensive in the past year.
That figure has held steady for four consecutive years. It did not move in response to policy changes, rebate reform, or the wave of new transparency tools. The lived experience of prescription access, according to our 2026 State of Drug Access Report—a survey of 1,000 insured U.S. adults—has not meaningfully improved.
But cost is only half the problem. The other half is confusion. And confusion, it turns out, is doing more damage to member trust and plan spend than most employers and health plans realize.
More Than Half of Members Cannot Predict What They Will Pay
When members cannot anticipate their out-of-pocket cost at the pharmacy counter, they do not engage more carefully with their benefits. They disengage entirely.
The 2026 report found that 53.1% of insured consumers find it confusing to figure out their final prescription price. That is a majority experience not a fringe case. And price confusion has a direct behavioral consequence. Among members who report price confusion, only 32.2% trust they are paying the lowest available price. Among those who do not find it confusing, that confidence jumps to 58.1%.
Confusion erodes trust. And eroded trust drives workarounds. Members who find pricing confusing are more likely to use discount cards and bypass their benefit entirely—79.6% of price-confused members reach for a discount card at the pharmacy counter. The benefit design your plan spent months optimizing gets circumvented before the member even fills the prescription.
This is not a pharmacy education problem. It is a structural design problem. The system was built to reveal cost at the point of sale, essentially, the worst possible moment for a member to absorb complexity, make a rational decision, or seek help.
Medication Overload Is a Workforce Problem, Not Just a Clinical One
Polypharmacy—taking five or more medications—is increasingly common among working-age adults. And the 2026 report makes clear that the burden is not primarily clinical. It is cognitive.
Nearly two-thirds of respondents managing five or more medications describe the experience as confusing, side-effect-heavy, or difficult to manage. The demographic concentration is telling: adults ages 35–44 most frequently reference organizational burden. These are your working-age people who are managing careers, families, and a stack of prescriptions that no one has ever reviewed as a complete picture.
Respondents in this group describe the experience in their own words: keeping track of refill schedules and which medication does what feels like a second job. Some report adjusting doses on their own because managing everything exactly as prescribed is simply too confusing. That is not a motivation failure. That is a systems failure.
The downstream cost is real. Members who miss doses or self-adjust are members whose conditions go less managed. That generates avoidable utilization that shows up in the medical line, not the pharmacy line, which is exactly why it goes unattributed and unaddressed.
Prior Auth Friction Does Not Delay Care Equally
Nearly 38% of insured consumers have had a prescription denied or delayed due to prior authorization. That figure has held at approximately 30–40% for four consecutive years. It does not improve. It compounds.
The outcomes data is instructive. Among those who hit a PA wall, 61.1% eventually received their medication after completing the paperwork. But 10% were denied and never received the drug. And 4.8% simply gave up. The abandonment rate is not dramatic on its own, but it concentrates heavily among younger adults, the segment with the least institutional knowledge to navigate the appeals process and the most to lose from interrupted therapy.
For employees ages 18–24, the denial rate after a PA encounter is 31.2, which is more than three times higher than for adults ages 55–64. Administrative barriers, the data shows, do not distribute harm evenly. They redistribute it onto the people least equipped to fight back.
Each of these experiences: the confusing price, the unanswered PA, the medication stack no one has reviewed lands as an escalation. The member calls HR. They call the pharmacist. They call their doctor. Or they stop engaging altogether. Every one of those outcomes has a cost.
Members Are Not Calling Their Insurer. They Are Calling Their Doctor.
When a prescription is too expensive, 46.2% of consumers call their doctor to request a lower-cost alternative. Only 11% call their insurance company. The physician has become the de facto cost navigation resource not by design, but by default.
This pattern has held for four years running. And it is one of the most actionable findings in the entire dataset, because it tells you exactly where trust lives in the pharmacy experience. Not with the plan. Not with the PBM. With the prescriber.
The demand for physician-directed solutions is similarly durable. 83.9% of consumers want their provider to automatically switch them to the lowest-cost clinically appropriate option. That preference has remained stable across four consecutive years of polling, with no erosion by demographic or age group. Even among the 51% of members whose doctor already helps with drug costs, 88.8% still want automatic switching built in.
The consumer has already decided. They want the system to absorb the complexity so they do not have to. The question is whether the system is designed to deliver that or whether it keeps pushing the burden back onto the member.
Trust Is the Metric That Follows You Everywhere
The 2026 report surfaces a finding that benefits teams should take personally: drug affordability programs do not just affect pharmacy costs. They affect how members feel about their plan overall.
Among members who are aware their employer or health plan offers a drug savings program, 58.4% trust they are paying the lowest price. Among those who say no program exists, that number drops to 36.9%. And 76.1% of members say they would view their plan more favorably if it offered a drug savings program—with the strongest favorability lift (82.3%) coming from the members who currently have the least trust.
This is a direct line from pharmacy experience to plan satisfaction. The member who abandons a prescription due to confusion is not just a clinical risk. They are a retention risk. They are an HR escalation. They are a story told at the lunch table that shapes how the next open enrollment goes.
Fix the Signal, Not the Noise
Four years of data converge on a single conclusion: consumers want affordability handled inside care delivery, before prescriptions reach the pharmacy counter, and without requiring them to navigate tradeoffs on their own.
They are not asking for another app. They are not asking for better mailers. Fifty-five percent of people who already use apps to search for lower-cost medications find it too hard. Self-navigation tools work for the motivated and the healthy. They consistently fail the people who need the most help.
The physician workflow is where decisions are already made and where member trust is highest. Routing guidance through that channel automatically, within existing workflows, without creating new touchpoints is the only intervention the data has consistently supported.
The confusion tax is real, it is measurable, and it is entirely preventable. The data says so. Your HR escalation log probably does too.
Source: RazorMetrics 2026 State of Drug Access Report. Survey of 1,000 insured U.S. adults, conducted December 2025, weighted to reflect national demographics.
